Comparable long-term outcomes with biosimilar and originator adalimumab in juvenile idiopathic arthritis: a multicenter cohort study
- 26 August 2026
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (9) , 1021-1029
Abstract
1. Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood and may lead to substantial morbidity due to persistent inflammation and irreversible joint damage i...Keywords
This publication has 34 references indexed in Scilit:
- Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid ArthritisJAMA Network Open, 2023
- Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patientsPharmacology Research & Perspectives, 2022
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated UveitisArthritis Care & Research, 2019
- The Science Behind BiosimilarsArthritis & Rheumatology, 2018
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2015
- Development and Retrospective Validation of the Juvenile Spondyloarthritis Disease Activity IndexArthritis Care & Research, 2014
- Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity scoreArthritis & Rheumatism, 2012
- American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisArthritis Care & Research, 2011
- Development and validation of a composite disease activity score for juvenile idiopathic arthritisArthritis Care & Research, 2009
- The burden of rheumatoid arthritis and access to treatment: health burden and costsThe European Journal of Health Economics, 2007